Table 1 Baseline characteristics of patients with stricturing Crohn’s disease.
Parameter | N (%) (n = 59) | |
|---|---|---|
Age at presentation (Mean ± SD) | 30.1 ± 15.6 | |
A1 | 16 (27.1%) | |
A2 | 24 (40.7%) | |
A3 | 19 (32.2%) | |
Sex (%) | ||
Male | 41 (69.5%) | |
Female | 18 (30.5%) | |
Median disease duration of disease (range) (months) | 124 (30–396) | |
Overall median duration of follow up (range) (months) | 42 (8–180) | |
Median duration between disease onset and initiation of biologics (months) | 72 (50–120) | |
Median duration of follow up after initiation of biologics (months) | 26 (16–50) | |
Clinical symptoms | ||
Diarrhoea | 25 (42.4%) | |
Abdominal pain | 31 (52.5%) | |
Blood in stools | 16 (27.1%) | |
Subacute intestinal obstruction | 6 (10.2%) | |
Perianal fistula | 9 (15.3%) | |
Anaemia at baseline | 35 (59.3%) | |
Extra intestinal manifestations | 11 (18.6%) | |
Disease location (L), n (%) | Terminal Ileal ± ileocaecal (L1) | 13 (22.0%) |
Colonic (L2) | 14 (23.7%) | |
Ileocolonic (L3) | 12 (20.3%) | |
Upper gastrointestinal (L4) | 13 (22.0%) | |
L1 + 4 (with upper GI modifier) | 6 (10.2%) | |
L3 + 4 (with upper GI modifier) | 1 (1.7%) | |
Location of stricture (%) | Ileal | 41 (69.5%) |
Jejunal +/− Ileal | 6 (10.2%) | |
Colonic | 12 (20.3%) | |
Number of strictures | ||
Single | 21 (35.6%) | |
Multiple | 38 (64.4%) | |
Stricture noted on endoscopy | 27 (45.8%) | |
Baseline Haemoglobin (mean ± SD) (gm/dl) | 9.3 ± 2.0 | |
Baseline Albumin (mean ± SD) (gm/dl) | 3.3 ± 0.85 | |
Steroid dependent disease | 33 (55.9%) | |
Steroid refractory disease | 22 (37.3%) | |
≥ 3 courses of steroids | 20 (33.9%) | |
Azathioprine received (overall) | 52 (88.0%) | |
Concomitant immunomodulators | ||
Azathioprine | 28 (47.8%) | |
Methotrexate | 4 (6.8%) | |
Therapeutic ATT trial | 23 (39.0%) | |
